Clinical Trial: Mobile and Scalable Innovations for Measles Immunization: a Randomized Controlled Trial

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Unconditional Travel Subsidies on Measles Vaccination in Western Kenya: The Mobile and Sc

Brief Summary: The overall objective is to test the impact of short message service (SMS) reminders, with or without unconditionally provided mobile-money incentives, can improve measles vaccination coverage in rural western Kenyan infants.

Detailed Summary:
Sponsor: Johns Hopkins Bloomberg School of Public Health

Current Primary Outcome: Measles vaccination coverage [ Time Frame: 10 months ]

Proportion of children receiving measles vaccination by 10 months of age by study arm


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Time to measles vaccination (in days) using Kaplan-Meier Survival Analysis [ Time Frame: 12 months ]
    As a secondary analysis of the primary outcome, time-to-measles immunization curves will be constructed using the Kaplan-Meier method and study arms will be compared using the Cox model. The 25th, 50th, and 75th percentiles for time to immunization and the number of days delayed, in relation to the measles due date, will also be reported for each vaccine and by study arm.
  • Proportion of children who receive measles vaccination stratified by demographic variables [ Time Frame: 10 months ]
    A priori we will conduct sub group analyses of the primary outcome for mobile phone ownership, birth order of the enrolled caregiver's child, and time to clinic. Additional variables for subgroup analyses will come from a risk factor analysis of not receiving measles vaccination in the control arm
  • Measles vaccination coverage at 12 months [ Time Frame: 12 months ]
    Proportion of children who receive measles vaccination by twelve months of age by study arm
  • Vaccination coverage for second dose of measles vaccine at 24 months. [ Time Frame: 24 months ]
    This outcome is dependent on receiving more funding


Original Secondary Outcome: Same as current

Information By: Johns Hopkins Bloomberg School of Public Health

Dates:
Date Received: September 8, 2016
Date Started: November 2016
Date Completion:
Last Updated: September 13, 2016
Last Verified: September 2016